Abstract Disseminated tumor cells (DTCs) detected in the bone marrow (BM) of breast cancer patients identify women at high risk of recurrence. DTCs are traditionally detected by immunocytochemical staining for cytokeratins or single gene expression measurements, which limit both specificity and sensitivity. We evaluated the Nanostring nCounter TM platform for multi-marker, gene expressionbased detection and classification of DTCs in the BM of breast cancer patients. Candidate genes exhibiting tumor cell-specific expression were identified from microarray datasets and validated by qRT-PCR analysis in nonmalignant human BM and identical samples spiked with predefined numbers of molecularly diverse breast tumor cell lines. Thirty-eight validated transcripts were designed for the nCounter TM platform and a subset of these transcripts was technically validated against qRT-PCR measurements using identical spiked BM controls. Bilateral iliac crest BM aspirates were collected and analyzed from twenty breast cancer patients, prior to neoadjuvant therapy, using the full 38-gene nCounter TM code set. Tumor cellspecific gene expression by nCounter TM was detected with a sensitivity of one cancer cell per 1 9 10 6 nucleated BM cells after optimization. Measurements were quantitative, log linear over a 20-fold range, and correlated with qRT-PCR measurements. Using the nCounter TM 38-gene panel, 6 of 8 patients (75 %) who developed metastatic disease had detectable expression of at least one transcript. Notably, three of these patients had detectable expression of ERBB2 in their BM, despite the fact that their corresponding primary tumors were HER2/ERBB2 negative and therefore did not receive trastuzumab therapy. Four of these patients also expressed the PTCH1 receptor, a newly recognized therapeutic target based on hedgehog signaling pathway inhibition. The presumptive detection and classification of DTCs in the BM of breast cancer patients, based on sensitive and quantitative multi-marker detection of gene expression using the nCounter TM platform, provide an opportunity to both predict early distant recurrence and, more importantly, identify opportunities for preventing the spread of disease based on the expression of unique, therapeutically actionable gene targets. This study demonstrates the application of a new technology for multiplexed gene expression-based detection of DTCs in the BM of breast cancer patients and identifies at least two therapeutically targetable genes that are frequently expressed in the BM of patients who develop metastatic disease. 
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Introduction
Approximately 40,000 women die from breast cancer each year as a consequence of metastatic disease development. Data suggest that only a small, unique subset of cells within a primary breast tumor (less than 1 %) possess metastatic potential [1, 2] . Furthermore, molecular profiles of primary, heterogeneous tumors may demonstrate limited resemblance to those tumor cells that eventually progress to metastatic foci [3] . Clinically, therapies that reduce primary tumor mass by simply eliminating proliferating cells often fail to cure patients, particularly with respect to metastatic disease [4] . To develop new therapeutic strategies to control and monitor distant disease development, it is essential to identify and target the intermediary cells in the metastatic process since these cells likely have biologic behavior and therapeutic vulnerabilities which differ from the primary tumor [5] .
Disseminated tumor cells (DTCs) can be detected in the bone marrow (BM) of 30-40 % of early stage breast cancer patients [6] . Several large multi-institutional clinical trials have documented that the presence of BM DTCs at the time of diagnosis identifies women at high risk of recurrence. Those women with detectable DTC after completion of all adjuvant therapy are at higher risk of recurrent disease development than those women with no detectable DTC in their BM [7, 8] . The proposed biologic basis for this clinical observation is that BM serves as a reservoir that allows DTCs to adapt and disseminate to other organs [9] . Alternatively, it is possible that clinically detected BM DTCs may be a marker of body-wide dissemination of tumor cells rather than the body's only long-term reservoir [10] [11] [12] . Regardless, DTC detection allows the identification of women at high risk of recurrence and the ability to monitor response in those women with clinically undetectable disease.
Although the detection of DTCs in breast cancer is still investigational, its incorporation into clinical management of breast cancer patients is currently the focus of much research. Standardized guidelines have been published for the immnocytological (ICC) detection of DTCs [13] , which is the current gold standard and has a reported sensitivity ranging from 1 DTC in 10 5 -10 6 leukocytes [14] . Antibodies against epithelial-specific antigens such as cytokeratins (CK) or EpCAM, surface adhesion molecules, or growth factor receptors have been used for the detection of carcinoma cells due to the absence of more tumor-specific target antigens [15] . Other studies have assessed DTC detection using assays that detect single epithelial-or organ-specific transcripts such as cytokeratin 19 (KRT19), MUC1 [16] , urokinase-type plasminogen activator receptor (uPAR) [17] , EpCAM (TACSTD1), and mammaglobin (SCGB2A2) [18] [19] [20] [21] [22] [23] . Expression of SCGB2A2, KRT19, and TWIST1 in the BM of breast cancer patients has individually demonstrated prognostic significance [24] [25] [26] [27] . However, because individual gene expression is not always absolutely tumorspecific, false positive results can be observed due to low level transcription of epithelial or breast tissue-specific genes in normal BM cells [28, 29] . Conversely, given the known molecular heterogeneity of DTCs, it is unlikely that a single gene marker will be suitable for the detection of DTCs in all breast cancer patients. For example, KRT19 is not expressed by all DTCs; its expression is often lost in breast cancer cells during tumor progression and epithelial to mesenchymal transition (EMT) [30, 31] .
A multi-marker assay approach has the potential to overcome some of the above concerns by allowing the simultaneous, composite detection of multiple genes in a single sample [26, [32] [33] [34] . Analysis of DTC-associated molecular profiles could improve both sensitivity and specificity of DTC detection itself, and also provide prognostic or therapeutically predictive information for patients. The Nanostring nCounter TM (NC) assay platform allows for the simultaneous, quantitative detection of multiple (up to 600) nucleic acid targets in a single sample with a sensitivity and reproducibility comparable to qRT-PCR [35, 36] . Accordingly, we have mined existing gene expression microarray data to identify and validate gene transcripts, the expression of which is specifically associated with breast tumor cells and absent in normal BM cellular constituents. We have adopted a panel of 38 of these genes to the NC platform, and in this study demonstrate how the assay can be used with sufficient sensitivity to profile clinical BM samples from breast cancer patients to detect and potentially classify rare BM-associated DTCs. In a cohort of twenty patients, eight of whom had distant metastatic recurrence within 48 months, composite patterns of gene expression identified patients more likely to develop metastatic disease and who might be candidates for targeted therapeutics directed to both ERBB2 and PTCH1 gene expression.
Methods

Study population
Control BM specimens were collected from healthy female volunteers after informed consent. DTC-positive BM previously assessed by immunohistochemistry was obtained retrospectively from a biospecimen collection associated with a previously reported therapeutic trial [37] . Specimens for the test clinical cohort were also obtained retrospectively from an independent, ongoing IRB-approved BM and tissue banking breast cancer protocol at our institution.
All patient BM aspirates were collected prior to the initiation of any therapy. An overview of clinical samples used in this study is shown in Supplemental Table 1. BM aspiration, processing, and RNA isolation For all breast cancer cases, 20 ml of BM was collected from the right and left anterior iliac crests, subjected to hypotonic RBC lysis, washing, and nucleated cell counting within 2 h from the time of collection. For controls, BM was harvested unilaterally. For whole BM analysis, 5 9 10 6 nucleated cells were pelleted and immediately snap frozen for subsequent RNA isolation. For mononuclear cell enrichment, whole BM was diluted fivefold in RPMI media and processed using a standard Ficoll-Hypaque gradient technique. The enriched mononuclear cell fraction was then counted and 5 9 10 6 mononuclear cells were pelleted and snap frozen for subsequent RNA isolation. SKBR3 (ER-/Her2?), MDA/ MB231 (ER-/Her2-), and ZR75 (ER?/Her2-) human breast cancer cells were trypsinized from plates during log growth phase, washed, counted, diluted into the prepared nucleated cell fraction of normal human BM samples at incremental fivefold dilutions from 1:1,000 to 1:500,000 tumor cells per nucleated cell count, pelleted, and snap frozen for subsequent RNA isolation. All RNA isolations were performed from snap frozen cell pellets using Trizol reagent (Invitrogen) as previously described [27] . RNA was quantified by A 260 using a Nanodrop spectrophotometer and qualitatively assessed using an Agilent bioanalyzer. All RNAs used for qRT-PCR or NC analysis demonstrated a RIN score of [7. 0.
qRT-PCR analysis
SyBr green or TaqMan Assay-on-Demand primer/probe sets for indicated transcripts were purchased from Applied Biosystems. Primer/probe sequences are shown in Supplemental Table 2 . One microgram of total RNA was reverse-transcribed and 1/100th of the cDNA template was used in each replicate qPCR reactions. Each reaction consisted of 1 ll of cDNA, TaqMan Master Mix (Applied Biosystems), and 59 primer/probe set in a total volume of 20 ll, following the manufacturer's standard protocol. For each transcript/sample, duplicate or triplicate reactions were performed in an ABI 7500 FAST Sequence Detection System. Replicated sample assays with a cycle threshold (CT) value difference of greater than 1.5 (outliers) were excluded from analysis. Each run with a gene primer set was normalized to CT values of GAPDH primer set on the same cDNA sample. This value was in turn normalized across the entire sample set by means of the average delta CT from an identical analysis using a set of four normal volunteer BM specimens, using the ddCT method [38] .
In samples where a specific transcript was not detected (CT [ 40) , the fold difference in expression was defined as 1.0 (equal to that of the normal bone BM average).
Nanostring nCounter assay
The nCounter assay was performed with the 38-gene code set as previously described [8] with the exception that input RNA was increased from 0.5 to 5 lg to increase the sensitivity for detecting transcripts expressed only by rare DTC populations. Eleven positive and nine negative control spikes were used to calibrate the assay. Mean hybridization counts of the negative controls were subtracted from all other transcript counts to correct for background [34] . Patient samples were run in duplicate or triplicate and the average value taken for analysis. Reference values for each gene were calculated from cohorts of 8 and 11 BM samples from healthy female volunteers. All expression values were normalized based on the average expression of three internal control transcripts (TBP, RPR0, POL2RA). For binary analysis, a sample was considered positive for gene expression if hybridization counts were 2 standard deviations above the mean of the healthy control BM population.
Statistical methods
Spearman's rank correlation coefficient was calculated on PCR and NC data after removing values at the extreme of the measurement. Coefficient of variation was calculated on normal BM specimens to assess the variance within controls. Assessment of variance within patient samples was carried out treating differences between patient samples as signal and differences within patient samples as noise.
Results
Target gene selection
To identify gene transcripts that could potentially serve as specific markers for DTCs in the context of patient BM, we analyzed gene expression microarray data from 80 primary breast tumors, 79 serial BM samples with and without known DTC involvement (based on immunocytochemistry) from 25 breast cancer patients, 5 BM samples from healthy volunteers, as well as additional breast tumor datasets in the literature [27, 39, 40] . Comparative expression analysis of these datasets identified genes that had detectable microarray-based expression in either primary tumors and/or ICCpositive BM specimens, but were not detectable in similar datasets from healthy volunteer BM or in ICC-negative breast cancer patient BM. A total of 69 genes met these criteria (Supplemental Table 3 ). To further validate their tumor-specific expression, each gene was quantified by qRT-PCR using a set of healthy volunteer BM samples and three exemplar breast tumor cell lines of differing molecular subtypes: SKBR3 (HER2?), ZR75 (ER?), or MDAMB231 (HER2-/ER-). Of the 69 genes chosen, 27 genes met the criteria of undetectable or nearly undetectable expression (defined as CT [ 37) in healthy volunteer BM and a minimum of 20-fold (range 20-18,000) higher expression in at least one of three breast cancer cell lines relative to the healthy control population. Eleven genes (CCND1, ESR1, FGFR4, Gli2, Gli3, GSC, IGFBP4, PDGFRB, PTCH1, SMO, SNAI1) were expressed at less than 20-fold over that in healthy BM, but were included in the panel due to their biologic and/or clinical relevance (Supplemental Table 4 ). Figure 1 lists the genes that comprise the full 38-gene panel, along with their biologic process associations.
nCounter performance comparison
Transcript expression analysis by qualitative or semiquantitative RT-PCR remains the most documented approach for molecular detection of breast cancer DTCs, primarily because of the requisite sensitivity that amplification methods can provide. To determine whether the non-amplification-based nCounter platform could have sufficient sensitivity to detect gene expression from rare DTCs amidst a high background of normal BM constituents, we examined the expression of a subset of nine genes (TWIST1 [27] , SNAI2 [41] , EPCAM [42, 43] , SCGB2A2 [44] , EGFR [45] , PITX2 [46] , S100A3 [27] , KRT17, and KRT19 [47] ) from the 38-gene panel in the three exemplar breast cancer cell lines serially diluted into normal human BM. As shown in Table 1 and Fig. 2 , expression measurements were quantitative and varied over a 20-fold linear dynamic range. Consistent with previous reports [48, 49] , not all of the nine genes were detected in each of the cell lines, demonstrating the necessity of a multi-gene marker panel for detecting DTC expression from cells of varying molecular phenotypes. Although KRT19 transcript was detected in BM samples spiked with each of the cell lines, each cell line demonstrated a unique pattern of expression of one or more genes.
In parallel, the same sample dilution series was used for single gene qRT-PCR expression analysis. For those genes with detectable expression by nCounter assay, expression levels measured by qRT-PCR and nCounter demonstrated good correlation over the full dynamic range (Fig. 2 ). Spearman's rank correlation coefficient between qRT-PCR (expressed as fold increase over expression in non-malignant BM) and nCounter (expressed as hybridization counts over that from non-malignant BM) for KRT19, S100A3, SCGB2A2, TACSTD1, and TWIST1 ranged from .80 to .99 in those cell lines that expressed the individual genes.
Using 0.5 lg of input RNA, KRT19 expression could be detected at a level of one cancer cell per 100,000 nucleated BM cells. However, the limits of reported detection using conventional immunocytochemistry have been reported at one cancer cell per 1 million nucleated BM cells, theoretically ten times more sensitive [13] . Therefore, to increase the sensitivity of the assay, we modified the standard protocol to perform mononuclear cell enrichment (a standard procedure employed for ICC analysis) and increased input RNA to five micrograms, a quantity of analyte that is still readily obtainable from a routine BM aspiration. Mononuclear cell enrichment increased expression signal levels by approximately twofold, while as expected a tenfold increase in RNA input increased expression signals proportionally by tenfold as well (Supplemental Table 5 ). Not surprisingly, some transcripts that previously demonstrated nominal expression in normal BM cell constituents (SNAI2, TACSTD1, S100A3, KRT17) had higher background expression using the modified protocol, while background expression of several other transcripts (KRT19, EGFR, TWIST1, SCGB2A2, PITX2) was unaltered by the protocol modification. Importantly, the protocol modification allowed us to achieve a theoretic sensitivity of one DTC per one million nucleated BM cells, the generally accepted limit of sensitivity observed with the ''gold standard'' ICC detection.
Analysis of BM from breast cancer patients
To demonstrate the clinical applicability of this method, the nCounter nine-gene panel was first tested in five BM samples collected from patients with stage II/III breast cancer prior to any treatment, who had previously documented DTCs in their BM by ICC (Table 2) . A ''normal range'' for BM expression of each gene was established by analyzing BM from eight female healthy volunteers. Intra-class correlation coefficient which compares within patient variance to total noise variance was calculated for the nine genes and this ranged from .622 to .909. At least one gene transcript was detected above the background BM signal in four of the five breast cancer BM samples. Although, from this small sample set, a composite pattern of expression based on primary tumor molecular phenotype was not obvious, two ER-/ Her2-breast cancer cases had detectable BM expression of several genes known to be expressed in this subtype of primary breast cancer (EPCAM, SNAI2, KRT17). Interestingly, KRT19 gene expression, a molecular marker often used for detection of DTCs, was detected in only one of the five patient specimens.
Having documented performance characteristics of the assay and applicability to primary BM samples from breast cancer patients with known DTCs, we analyzed retrospectively collected bilateral BM from an independent cohort of twenty clinical stage II/III breast cancer patients and an additional reference set of 11 healthy female volunteers, using the entire 38-gene panel. Eight of twenty patients developed metastatic disease within 2-48 months of primary diagnosis (mean 23 months), while twelve had no evidence of metastatic disease at 3-5 years of followup. As shown in Fig. 3, 20 transcripts of the 38-gene panel were expressed above background in at least one BM sample, while at least one transcript was expressed above background in 17 patients (85 %). None of the BM specimens in this cohort had detectable expression of KRT19 and only four patients (20 %) had detectable expression of EPCAM, two genes commonly used for the molecular detection or selection of DTCs. Most patients demonstrated unique patterns of gene expression in BM. However, with only a few notable exceptions (Fig. 3, patient 3709 ), patterns of gene expression were highly concordant between right and left BM samples from the same patient in 11 of 20 cases. Unsupervised, hierarchical clustering of expression data demonstrated no obvious subclassification of cases, particularly with regard to molecular phenotype of the primary tumor or the occurrence of eventual metastases. Although 6 of the 8 patients (75 %) who developed metastatic disease had detectable expression of at least one of the 38 genes in their BM, patients who remained disease-free had a mean number of detectable transcripts that were not significantly different than that of patients with metastatic relapse. However, at the level of individual gene analysis, two transcripts (SNAIL2 and LAMB1) demonstrated a significantly different level of expression in the BM from patients who relapsed versus those who remained diseasefree (p = .0013 and .0014, respectively, with correction for multiple comparisons). One additional transcript from the 38-gene signature (IGFBP4) also demonstrated expression differences that were close to significance between the disease-free and metastatic patient populations (p = .058). Notably, several genes that are known targets for therapeutic intervention-ERBB2, PTCH1, and PDGFRB-were also expressed in the BM of patients who eventually developed metastatic disease. Of the eight patients with metastatic relapse, one or more of these therapeutic targets were expressed in four patients (50 %). Four of six patients with PTCH1-positive marrow eventually developed metastatic disease and therefore could have potentially benefited from adjuvant therapy directed to gene in the Hedgehog pathway. Three of four patients (Fig. 4) with HER2-negative tumors and ERBB2-positive DTC eventually developed metastasis, while none of the patients with HER2-positive tumors and ERBB2-positive BM who received therapy with traztuzumab developed metastasis. For this set of patients, there was good concordance between detection of selected genes by PCR and NS (Supplemental Table 7 ).
Discussion
The presence of DTCs in the BM of breast cancer patient has important prognostic and therapeutic implications. Adjuvant therapy administration is generally based on the primary tumor characteristics and lymph node status. However, those women with no detectable disease in their lymph nodes or BM remain at very low risk of recurrence and may not benefit from adjuvant treatment [50] . Conversely, patients who have completed adjuvant therapy, but retain residual micro-metastatic disease could benefit from further therapy. DTCs are heterogeneous [51, 52] , can persist for years and remain a predictor for disease recurrence [53] , may exhibit a stem cell-like chemotherapy resistant phenotype [54] , and likely have varying metastatic capabilities. Patients with detectable DTCs in their BM after chemotherapy treatment have a particularly poor prognosis indicating that chemotherapy does not eliminate all DTCs and that those subpopulations of DTCs which Axis is plotted in log scale survive cytotoxic chemotherapy have a high metastatic potential [55] . Persistence of DTCs in the BM years after diagnosis and initial therapy has been shown to be an indicator of subsequent systemic treatment failure [7, 8, 32] . Persistence or disappearance of DTCs after systemic treatment could therefore be used as a surrogate marker of treatment response [56] . Assays that detect and molecularly classify residual micro-metastatic disease could greatly benefit and guide the treatment of patients. Currently, the ''gold standard'' for DTC detection is ICC which is laborious and often limited in sensitivity and specificity, given the heterogeneity of DTCs. Molecular assays based on the detection of single, ''epithelial-specific'' transcripts such as EPCAM or KRT19 often perform no better than ICC-based methods [57] . Given the known heterogeneity of DTCs, multiplexed biomarkers could provide improved sensitivity and specificity for detection and classification, but the ability to effectively multiplex multiple markers in a single reaction while maintaining high specificity and sensitivity for each marker in clinical specimens has been limited and few studies have been published regarding the genomic profiling of DTCs [14] . A major challenge lies in identifying a panel of genes that are biologically relevant, representative of all possible breast cancer molecular subtypes, and have very absent or minimal expression in non-malignant BM constituents. Thus, a gene such as CD44, the expression of which is related specifically to the breast cancer stem cell phenotype and metastases, is not useful in this assay since it is expressed in multiple hemapoietic cells [58] .
The Nanostring nCounter platform provides an attractive approach for performing multiplexed gene expression assays in a single reaction and can quantitatively detect expression of up to 600 gene transcripts in a single reaction with similar sensitivity and reproducibility as amplification-based methods [34] . Most importantly, the assay does not require high quality RNA and the direct readout of the transcript copy number provides a higher precision for detecting gene expression originating from minor cell populations. In fact, we were surprised to find in our validation studies that the assay could detect minimally to moderately abundant transcripts specifically emanating from as few as one tumor cell in a background of one million BM cells, comparable to current ICC detection methods. This sensitivity was facilitated by enrichment of the mononuclear cell fraction of the BM, increasing assay RNA input by tenfold without signal saturation, and careful selection of transcripts which demonstrated absent or minimal expression in BM cell populations.
Despite selecting target transcripts which were expressed in one or more of three archetypical breast tumor cell lines of varying molecular phenotype, several of the genes in our 38-gene panel were not detected in the twenty cases of primary BM from breast cancer patients analyzed in this study. It is possible that the expression of many of these genes is restricted to tumor cell lines or that our patient Table 7 population in this study was too small to fully sample the diversity of DTC molecular phenotypes. For example, we found that 1 of 5 samples in our first validation cohort was TWIST1 expression positive, but none of the twenty samples in the second cohort had detectable levels of expression above background. In this regard, the flexibility of easily introducing or removing transcript probes in an iterative design approach for the nCounter assay proved particularly useful for the current study and for future studies, it will allow the easy introduction of new targetable genes. Conversely, we found that 65 % of patients in our patient cohort demonstrated expression of at least one transcript in at least one of their bilateral BM specimens. This far exceeds previously reported positivity based upon ICC detection of DTCs and clearly, many patients with a positive gene signature remained relapse-free for more than 5 years. There are several possible explanations for this result. First, although gene expression levels were referenced to a population of healthy female controls, it is possible that the reference population size was not sufficiently large to fully capture inter-individual variability that may exist in healthy BM. Second, since it is not possible to specifically equate expression from the 38-gene panel with the presence of tumor cells, gene expression in some patients could originate from rare BM cell elements specifically present in the cancer patient population. Such a cancer-specific ''stromal response'' could still be biologically and clinically significant, even if it is not indicative of actual DTCs residing in the BM. Finally, it is possible that 65 % of our population do actually harbor DTCs in their BM. Detection by CK ICC may underestimate the percentage of DTC-positive patients, particularly for those DTCs that have undergone EMT and concomitant loss of CK expression [59] . Since only 6 of 17 patients (30 %) with positive gene expression developed distant metastases within five years, it is possible that some BM DTCs may have attenuated metastatic potential that can be directly related to their individual expression profiles.
In this regard, it was striking to see that patterns of DTC expression demonstrated such variability between patients. This cannot likely be attributed to biologic noise since bilateral BM aspirates demonstrated, except in a few cases, high concordance in expression patterns. In fact, it might be expected that in some patients, due to sampling bias, bilateral samplings may not be completely concordant. The molecular diversity of gene expression observed in this small subset of patients as well the biologic processes that cancer cells undergo during their transition in the hematologic system underscores the need for a multiplexed gene expression panel. Furthermore, patterns of DTC gene expression did not appear to be directly related to the molecular phenotype of the primary tumor. In fact, several tumors that were Her2 negative corresponded to patient BM samples with ERBB2 expression, while two of the six patients with Her2-positive tumors had detectable expression of ERBB2 in their BM and were also positive for other transcripts. Although the composite 38-gene expression pattern did not immediately classify patients based upon disease relapse, and in fact more than half of patients with a transcript-positive BM did not relapse, we identified several individual genes within the 38-gene signature that did reach a significant correlation with disease relapse-LAMB1 and SNAI2. In fact, SNAI2 expression was inversely correlated with disease relapse, suggesting that expression patterns may be related to ''favorable'' as well as ''unfavorable'' DTC molecular phenotypes.
Beyond providing prognostic information, several genes in the 38-gene panel are also relevant therapeutic targets-ERBB2, EGFR, ESR1, PDGFB, PTCH1-and were expressed in patient BM specimens, often in non-overlapping patterns. This finding, together with the fact that expression of individual target genes such as ERBB2 is often expressed discordantly in primary tumors and corresponding DTCs, suggests a utility for using DTC molecular profiles to ''personalize'' adjuvant therapy in a prospective clinical trial setting. Although all specimens analyzed in the current study were collected only prior to therapy, this assay could also be applied to monitoring therapeutic efficacy in the adjuvant setting for those patients without radiographic or clinical evidence of disease. BM aspirations for DTCs performed before and following therapy and at time points during follow-up could lead to real-time assessments of therapeutic efficacy and identify those patients in need of continued therapy. Subsets of DTCs that persist or are eliminated by therapy could be monitored and targeted. This type of assay platform for clinical samples could facilitate translation of multi-gene biomarkers into the clinic, identify women at high risk of breast cancer recurrence, and provide guidance on tailored therapies based on the molecular profile of micro-metastatic breast tumor cells.
